Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Coherus Biosciences Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS
Ticker
Exchange
SIC #
Website
Latest Ticker
CHRS
Nasdaq
2833
https://www.coherus.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Coherus Biosciences Inc
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
- Jun 5th, 2023 9:30 pm
Even Mark Cuban Can’t Fix This Broken Drug System
- Jun 5th, 2023 1:46 pm
UPDATE 2-Coherus BioSciences to launch Humira biosimilar at 85% discount
- Jun 1st, 2023 1:37 pm
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
- Jun 1st, 2023 12:33 pm
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
- Jun 1st, 2023 12:30 pm
UPDATE 1-FDA flags issues at Coherus partner's China manufacturing site for cancer drug
- May 31st, 2023 5:34 pm
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
- May 22nd, 2023 12:30 pm
Coherus Prices Public Offering of Common Stock
- May 16th, 2023 10:50 am
Coherus Announces Proposed Public Offering of Common Stock
- May 15th, 2023 8:01 pm
News Flash: 8 Analysts Think Coherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Are Under Threat
- May 13th, 2023 12:11 pm
Q1 2023 Coherus BioSciences Inc Earnings Call
- May 9th, 2023 4:48 pm
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
- May 8th, 2023 9:25 pm
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
- May 8th, 2023 8:05 pm
Coherus BioSciences to Present at Upcoming Investor Conferences in May
- May 4th, 2023 8:30 pm
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
- May 1st, 2023 8:07 pm
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 27th, 2023 12:05 pm
Coherus BioSciences, Inc. (NASDAQ:CHRS) Held Back By Insufficient Growth Even After Shares Climb 30%
- Apr 17th, 2023 10:51 am
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
- Apr 14th, 2023 6:45 pm
6 analyst picks: Lululemon sparkles | Pro Recap
- Mar 29th, 2023 7:30 am
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 64% over the last three years
- Mar 27th, 2023 3:38 pm
Scroll